Valneva

Valneva is a specialized biotechnology firm founded in 2012, focusing on the research, development, and manufacturing of vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company operates within the pharmaceutical and chemical manufacturing sectors, leveraging advanced R&D to create innovative preventative solutions. Valneva maintains a robust international footprint with operations spanning across Europe, including facilities in Sweden and the United Kingdom, supporting its mission to address critical public health challenges through integrated commercial vaccine production.

The organization currently maintains a workforce of 500-1,000 employees, distributed across 5 global locations. This operational scale enables Valneva to manage complex clinical development stages and large-scale manufacturing efforts effectively. Meet Valneva's team to gain insights into the leadership and technical expertise driving their vaccine development pipeline. The company’s infrastructure is designed to support both internal research initiatives and third-party commercialization efforts, ensuring a steady progression of vaccine candidates from laboratory research to market access.

Financially, Valneva demonstrates significant market activity, reporting annual revenue of $228.2M. As a publicly traded entity on the EPA under the ticker VLA, the company continues to secure strategic funding, including recent corporate investments and debt financing to bolster its long-term shareholder value. Explore financial highlights to review detailed metrics regarding their capital structure, funding history, and fiscal performance. Valneva remains a key player in the biotech landscape, consistently generating data to support its commercial-stage vaccine portfolio.